025sek
-2,0 %
Date:2024-05-17Time:15:26:19Latest report:Q4-2023List:First NorthTicker:XINT
Market Cap:139 msekEnterprise Value:131 msekNet Sales:0,08 msekEarnings:-54,1 msekEmployees:0ISIN:SE0007756903

Ratios

10-year key figure history for Xintela turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Xintela with index and moving average MA50 and MA200.

Stockprice:0,25
MA50:0,27
MA200:0,26
Price/MA200:-5,8 %
RSI (14):41,8
Price/MA50:-7,7 %

Description

Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.

Biotechnology